koto_feja
Merck (New York Stock Exchange:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) on Saturday announced interim results from a Phase 2 trial for lung cancer patients treated with ifinatamab deruxtecan (I-DXd), which belongs to a new class of cancer drugs called antibody-drug conjugates (ADCs).
Quoting a According to data as of April 25, the duo claimed that I-DXd at doses of 12 mg/kg and 8 mg/kg was effective against small cell lung cancer, leading to confirmed objective response rates (ORRs) of ~55% and ~26%, respectively.
Detailed results from the IDeate-Lung01 trial indicated that the 12 mg/kg dose was associated with 23 partial responses, while the 8 mg/kg dose was associated with one complete response and 11 partial responses.
With a median follow-up of 15.3 months and 14.6 months for the two-dose group, the median overall survival reached 11.8 months and 9.4 months for the 12 mg/kg and 8 mg/kg doses, respectively.
The companies also announced preliminary responses in brain-injured patients, noting that their intracranial ORRs reached 50.0% and 66.7% in the two dose groups.
Regarding safety, 17% of patients at the 12 mg/kg dose and 6.5% at the 8 mg/kg dose discontinued the trial due to adverse events.
The global, two-part study involved patients with extensive-stage small cell lung cancer who had undergone a median of two prior lines of therapy, including more than 75% who had received immunotherapy.
Merck (MRK) and Daiichi (OTCPK:DSNKY) have selected the 12 mg/kg dose for the dose expansion portion of the trial. The dataset is scheduled to be presented orally on Sunday at the World Conference on Lung Cancer in San Diego, California.